March 09, 2007

Allon Therapeutics Successfull in Early Trial of New Schizophrenia Medication

Allon Therapeutics Inc announced today that the results of the completed Phase Ib clinical trial of a new schizophrenia drug temporarily named "AL-108" met all of its early safety objectives. The trial confirmed that AL-108 is safe and well tolerated in 32 healthy elderly subjects after seven days of dosing. This test is only a very early test of what will be a three phase FDA testing program, which will likely take 3 to 5 more years. Only after successfully passing these tests that prove effectiveness and safety, would the drug be made available to the public.

AL-108 was recently selected by the National Institute of Mental Health funded project TURNS (Treatment Unit for Research of Neurocognition in Schizophrenia) for another Phase II efficacy trial evaluating it as a treatment for Schizophrenia related cognitive impairment.

“These results are quite positive and validate the intranasal use for AL-108. Moreover, the pharmacokinetic profile is sufficiently robust to confirm the doses selected in the multiple Phase II trials now underway,” said Dr. Bruce Morimoto, Vice-President Drug Development at Allon.

Allon Therapeutics Inc. is a clinical-stage Canadian biotechnology company developing drugs that protect against neurodegenerative conditions which impact the body's central nervous system.

More Information: Allon Therapeutics, Inc.

Related Reading:

Early Cognitive Enhancement Therapy May Improve Emotional Intelligence in Schizophrenia

Cognitive Enhancement Drugs for Schizophrenia

Progress in Cognitive Drug Testing


Invega, the main active metabolite of Risperidone, was approved last December and is beginning to make its way into the hands of patients.
Here is someone's experience with it.
Has anyone else heard anything about it? I'd imagine it's very similar to Risperdal, which I have never tried but have heard really good and really bad things about.

Due to the nature of its function and the timing of its release, I imagine that it has something to do with their patent running out and Risperdal going generic in December 2007. We'll see.

Posted by: Cory Schulz at March 12, 2007 09:53 PM

Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required